The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Subcutaneous Vaccine Adjuvants Market Research Report 2025
Synopsis
Subcutaneous Vaccine Adjuvants is used for Subcutaneous injection of Vaccine Adjuvants. A vaccine adjuvant is any material which is incorporated with a vaccine for the purpose of enhancing the immune response of the vaccine. An adjuvanted vaccine will tend to have a higher, earlier, and longer-lasting immune response than a non-adjuvanted vaccine.
The global Subcutaneous Vaccine Adjuvants market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Subcutaneous Vaccine Adjuvants, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Subcutaneous Vaccine Adjuvants.
Report Scope
The Subcutaneous Vaccine Adjuvants market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Subcutaneous Vaccine Adjuvants market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Subcutaneous Vaccine Adjuvants manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agenus
Croda International
Seppic
OZ Biosciences
Phibro Animal Health
Associated British Foods
InvivoGen
Merck KGaA
CSL Limited
GSK
Dynavax Technologies
Novavax
Segment by Type
Infectious Diseases
Cancer
Others
Segment by Application
Research Applications
Commercial Applications
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Subcutaneous Vaccine Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Subcutaneous Vaccine Adjuvants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Subcutaneous Vaccine Adjuvants is used for Subcutaneous injection of Vaccine Adjuvants. A vaccine adjuvant is any material which is incorporated with a vaccine for the purpose of enhancing the immune response of the vaccine. An adjuvanted vaccine will tend to have a higher, earlier, and longer-lasting immune response than a non-adjuvanted vaccine.
The global Subcutaneous Vaccine Adjuvants market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Subcutaneous Vaccine Adjuvants, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Subcutaneous Vaccine Adjuvants.
Report Scope
The Subcutaneous Vaccine Adjuvants market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Subcutaneous Vaccine Adjuvants market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Subcutaneous Vaccine Adjuvants manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agenus
Croda International
Seppic
OZ Biosciences
Phibro Animal Health
Associated British Foods
InvivoGen
Merck KGaA
CSL Limited
GSK
Dynavax Technologies
Novavax
Segment by Type
Infectious Diseases
Cancer
Others
Segment by Application
Research Applications
Commercial Applications
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Subcutaneous Vaccine Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Subcutaneous Vaccine Adjuvants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Subcutaneous Vaccine Adjuvants Market Overview
1.1 Product Overview and Scope of Subcutaneous Vaccine Adjuvants
1.2 Subcutaneous Vaccine Adjuvants Segment by Type
1.2.1 Global Subcutaneous Vaccine Adjuvants Market Value Comparison by Type (2024-2030)
1.2.2 Infectious Diseases
1.2.3 Cancer
1.2.4 Others
1.3 Subcutaneous Vaccine Adjuvants Segment by Application
1.3.1 Global Subcutaneous Vaccine Adjuvants Market Value by Application: (2024-2030)
1.3.2 Research Applications
1.3.3 Commercial Applications
1.4 Global Subcutaneous Vaccine Adjuvants Market Size Estimates and Forecasts
1.4.1 Global Subcutaneous Vaccine Adjuvants Revenue 2019-2030
1.4.2 Global Subcutaneous Vaccine Adjuvants Sales 2019-2030
1.4.3 Global Subcutaneous Vaccine Adjuvants Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Subcutaneous Vaccine Adjuvants Market Competition by Manufacturers
2.1 Global Subcutaneous Vaccine Adjuvants Sales Market Share by Manufacturers (2019-2024)
2.2 Global Subcutaneous Vaccine Adjuvants Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Subcutaneous Vaccine Adjuvants Average Price by Manufacturers (2019-2024)
2.4 Global Subcutaneous Vaccine Adjuvants Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Subcutaneous Vaccine Adjuvants, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Subcutaneous Vaccine Adjuvants, Product Type & Application
2.7 Subcutaneous Vaccine Adjuvants Market Competitive Situation and Trends
2.7.1 Subcutaneous Vaccine Adjuvants Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Subcutaneous Vaccine Adjuvants Players Market Share by Revenue
2.7.3 Global Subcutaneous Vaccine Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Subcutaneous Vaccine Adjuvants Retrospective Market Scenario by Region
3.1 Global Subcutaneous Vaccine Adjuvants Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Subcutaneous Vaccine Adjuvants Global Subcutaneous Vaccine Adjuvants Sales by Region: 2019-2030
3.2.1 Global Subcutaneous Vaccine Adjuvants Sales by Region: 2019-2024
3.2.2 Global Subcutaneous Vaccine Adjuvants Sales by Region: 2025-2030
3.3 Global Subcutaneous Vaccine Adjuvants Global Subcutaneous Vaccine Adjuvants Revenue by Region: 2019-2030
3.3.1 Global Subcutaneous Vaccine Adjuvants Revenue by Region: 2019-2024
3.3.2 Global Subcutaneous Vaccine Adjuvants Revenue by Region: 2025-2030
3.4 North America Subcutaneous Vaccine Adjuvants Market Facts & Figures by Country
3.4.1 North America Subcutaneous Vaccine Adjuvants Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Subcutaneous Vaccine Adjuvants Sales by Country (2019-2030)
3.4.3 North America Subcutaneous Vaccine Adjuvants Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Subcutaneous Vaccine Adjuvants Market Facts & Figures by Country
3.5.1 Europe Subcutaneous Vaccine Adjuvants Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Subcutaneous Vaccine Adjuvants Sales by Country (2019-2030)
3.5.3 Europe Subcutaneous Vaccine Adjuvants Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Subcutaneous Vaccine Adjuvants Market Facts & Figures by Country
3.6.1 Asia Pacific Subcutaneous Vaccine Adjuvants Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Subcutaneous Vaccine Adjuvants Sales by Country (2019-2030)
3.6.3 Asia Pacific Subcutaneous Vaccine Adjuvants Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Subcutaneous Vaccine Adjuvants Market Facts & Figures by Country
3.7.1 Latin America Subcutaneous Vaccine Adjuvants Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Subcutaneous Vaccine Adjuvants Sales by Country (2019-2030)
3.7.3 Latin America Subcutaneous Vaccine Adjuvants Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Subcutaneous Vaccine Adjuvants Market Facts & Figures by Country
3.8.1 Middle East and Africa Subcutaneous Vaccine Adjuvants Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Subcutaneous Vaccine Adjuvants Sales by Country (2019-2030)
3.8.3 Middle East and Africa Subcutaneous Vaccine Adjuvants Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Subcutaneous Vaccine Adjuvants Sales by Type (2019-2030)
4.1.1 Global Subcutaneous Vaccine Adjuvants Sales by Type (2019-2024)
4.1.2 Global Subcutaneous Vaccine Adjuvants Sales by Type (2025-2030)
4.1.3 Global Subcutaneous Vaccine Adjuvants Sales Market Share by Type (2019-2030)
4.2 Global Subcutaneous Vaccine Adjuvants Revenue by Type (2019-2030)
4.2.1 Global Subcutaneous Vaccine Adjuvants Revenue by Type (2019-2024)
4.2.2 Global Subcutaneous Vaccine Adjuvants Revenue by Type (2025-2030)
4.2.3 Global Subcutaneous Vaccine Adjuvants Revenue Market Share by Type (2019-2030)
4.3 Global Subcutaneous Vaccine Adjuvants Price by Type (2019-2030)
5 Segment by Application
5.1 Global Subcutaneous Vaccine Adjuvants Sales by Application (2019-2030)
5.1.1 Global Subcutaneous Vaccine Adjuvants Sales by Application (2019-2024)
5.1.2 Global Subcutaneous Vaccine Adjuvants Sales by Application (2025-2030)
5.1.3 Global Subcutaneous Vaccine Adjuvants Sales Market Share by Application (2019-2030)
5.2 Global Subcutaneous Vaccine Adjuvants Revenue by Application (2019-2030)
5.2.1 Global Subcutaneous Vaccine Adjuvants Revenue by Application (2019-2024)
5.2.2 Global Subcutaneous Vaccine Adjuvants Revenue by Application (2025-2030)
5.2.3 Global Subcutaneous Vaccine Adjuvants Revenue Market Share by Application (2019-2030)
5.3 Global Subcutaneous Vaccine Adjuvants Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Agenus
6.1.1 Agenus Corporation Information
6.1.2 Agenus Description and Business Overview
6.1.3 Agenus Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Agenus Subcutaneous Vaccine Adjuvants Product Portfolio
6.1.5 Agenus Recent Developments/Updates
6.2 Croda International
6.2.1 Croda International Corporation Information
6.2.2 Croda International Description and Business Overview
6.2.3 Croda International Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Croda International Subcutaneous Vaccine Adjuvants Product Portfolio
6.2.5 Croda International Recent Developments/Updates
6.3 Seppic
6.3.1 Seppic Corporation Information
6.3.2 Seppic Description and Business Overview
6.3.3 Seppic Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Seppic Subcutaneous Vaccine Adjuvants Product Portfolio
6.3.5 Seppic Recent Developments/Updates
6.4 OZ Biosciences
6.4.1 OZ Biosciences Corporation Information
6.4.2 OZ Biosciences Description and Business Overview
6.4.3 OZ Biosciences Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.4.4 OZ Biosciences Subcutaneous Vaccine Adjuvants Product Portfolio
6.4.5 OZ Biosciences Recent Developments/Updates
6.5 Phibro Animal Health
6.5.1 Phibro Animal Health Corporation Information
6.5.2 Phibro Animal Health Description and Business Overview
6.5.3 Phibro Animal Health Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Phibro Animal Health Subcutaneous Vaccine Adjuvants Product Portfolio
6.5.5 Phibro Animal Health Recent Developments/Updates
6.6 Associated British Foods
6.6.1 Associated British Foods Corporation Information
6.6.2 Associated British Foods Description and Business Overview
6.6.3 Associated British Foods Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Associated British Foods Subcutaneous Vaccine Adjuvants Product Portfolio
6.6.5 Associated British Foods Recent Developments/Updates
6.7 InvivoGen
6.6.1 InvivoGen Corporation Information
6.6.2 InvivoGen Description and Business Overview
6.6.3 InvivoGen Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.4.4 InvivoGen Subcutaneous Vaccine Adjuvants Product Portfolio
6.7.5 InvivoGen Recent Developments/Updates
6.8 Merck KGaA
6.8.1 Merck KGaA Corporation Information
6.8.2 Merck KGaA Description and Business Overview
6.8.3 Merck KGaA Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Merck KGaA Subcutaneous Vaccine Adjuvants Product Portfolio
6.8.5 Merck KGaA Recent Developments/Updates
6.9 CSL Limited
6.9.1 CSL Limited Corporation Information
6.9.2 CSL Limited Description and Business Overview
6.9.3 CSL Limited Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.9.4 CSL Limited Subcutaneous Vaccine Adjuvants Product Portfolio
6.9.5 CSL Limited Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.10.4 GSK Subcutaneous Vaccine Adjuvants Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Dynavax Technologies
6.11.1 Dynavax Technologies Corporation Information
6.11.2 Dynavax Technologies Subcutaneous Vaccine Adjuvants Description and Business Overview
6.11.3 Dynavax Technologies Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Dynavax Technologies Subcutaneous Vaccine Adjuvants Product Portfolio
6.11.5 Dynavax Technologies Recent Developments/Updates
6.12 Novavax
6.12.1 Novavax Corporation Information
6.12.2 Novavax Subcutaneous Vaccine Adjuvants Description and Business Overview
6.12.3 Novavax Subcutaneous Vaccine Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Novavax Subcutaneous Vaccine Adjuvants Product Portfolio
6.12.5 Novavax Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Subcutaneous Vaccine Adjuvants Industry Chain Analysis
7.2 Subcutaneous Vaccine Adjuvants Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Subcutaneous Vaccine Adjuvants Production Mode & Process
7.4 Subcutaneous Vaccine Adjuvants Sales and Marketing
7.4.1 Subcutaneous Vaccine Adjuvants Sales Channels
7.4.2 Subcutaneous Vaccine Adjuvants Distributors
7.5 Subcutaneous Vaccine Adjuvants Customers
8 Subcutaneous Vaccine Adjuvants Market Dynamics
8.1 Subcutaneous Vaccine Adjuvants Industry Trends
8.2 Subcutaneous Vaccine Adjuvants Market Drivers
8.3 Subcutaneous Vaccine Adjuvants Market Challenges
8.4 Subcutaneous Vaccine Adjuvants Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Subcutaneous Vaccine Adjuvants Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Subcutaneous Vaccine Adjuvants Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Subcutaneous Vaccine Adjuvants Market Competitive Situation by Manufacturers in 2023
Table 4. Global Subcutaneous Vaccine Adjuvants Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Subcutaneous Vaccine Adjuvants Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Subcutaneous Vaccine Adjuvants Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Subcutaneous Vaccine Adjuvants Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Subcutaneous Vaccine Adjuvants Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Subcutaneous Vaccine Adjuvants, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Subcutaneous Vaccine Adjuvants, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Subcutaneous Vaccine Adjuvants, Product Type & Application
Table 12. Global Key Manufacturers of Subcutaneous Vaccine Adjuvants, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Subcutaneous Vaccine Adjuvants by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Subcutaneous Vaccine Adjuvants as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Subcutaneous Vaccine Adjuvants Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Subcutaneous Vaccine Adjuvants Sales by Region (2019-2024) & (K Units)
Table 18. Global Subcutaneous Vaccine Adjuvants Sales Market Share by Region (2019-2024)
Table 19. Global Subcutaneous Vaccine Adjuvants Sales by Region (2025-2030) & (K Units)
Table 20. Global Subcutaneous Vaccine Adjuvants Sales Market Share by Region (2025-2030)
Table 21. Global Subcutaneous Vaccine Adjuvants Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Subcutaneous Vaccine Adjuvants Revenue Market Share by Region (2019-2024)
Table 23. Global Subcutaneous Vaccine Adjuvants Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Subcutaneous Vaccine Adjuvants Revenue Market Share by Region (2025-2030)
Table 25. North America Subcutaneous Vaccine Adjuvants Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Subcutaneous Vaccine Adjuvants Sales by Country (2019-2024) & (K Units)
Table 27. North America Subcutaneous Vaccine Adjuvants Sales by Country (2025-2030) & (K Units)
Table 28. North America Subcutaneous Vaccine Adjuvants Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Subcutaneous Vaccine Adjuvants Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Subcutaneous Vaccine Adjuvants Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Subcutaneous Vaccine Adjuvants Sales by Country (2019-2024) & (K Units)
Table 32. Europe Subcutaneous Vaccine Adjuvants Sales by Country (2025-2030) & (K Units)
Table 33. Europe Subcutaneous Vaccine Adjuvants Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Subcutaneous Vaccine Adjuvants Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Subcutaneous Vaccine Adjuvants Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Subcutaneous Vaccine Adjuvants Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Subcutaneous Vaccine Adjuvants Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Subcutaneous Vaccine Adjuvants Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Subcutaneous Vaccine Adjuvants Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Subcutaneous Vaccine Adjuvants Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Subcutaneous Vaccine Adjuvants Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Subcutaneous Vaccine Adjuvants Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Subcutaneous Vaccine Adjuvants Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Subcutaneous Vaccine Adjuvants Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Subcutaneous Vaccine Adjuvants Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Subcutaneous Vaccine Adjuvants Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Subcutaneous Vaccine Adjuvants Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Subcutaneous Vaccine Adjuvants Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Subcutaneous Vaccine Adjuvants Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Subcutaneous Vaccine Adjuvants Sales (K Units) by Type (2019-2024)
Table 51. Global Subcutaneous Vaccine Adjuvants Sales (K Units) by Type (2025-2030)
Table 52. Global Subcutaneous Vaccine Adjuvants Sales Market Share by Type (2019-2024)
Table 53. Global Subcutaneous Vaccine Adjuvants Sales Market Share by Type (2025-2030)
Table 54. Global Subcutaneous Vaccine Adjuvants Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Subcutaneous Vaccine Adjuvants Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Subcutaneous Vaccine Adjuvants Revenue Market Share by Type (2019-2024)
Table 57. Global Subcutaneous Vaccine Adjuvants Revenue Market Share by Type (2025-2030)
Table 58. Global Subcutaneous Vaccine Adjuvants Price (US$/Unit) by Type (2019-2024)
Table 59. Global Subcutaneous Vaccine Adjuvants Price (US$/Unit) by Type (2025-2030)
Table 60. Global Subcutaneous Vaccine Adjuvants Sales (K Units) by Application (2019-2024)
Table 61. Global Subcutaneous Vaccine Adjuvants Sales (K Units) by Application (2025-2030)
Table 62. Global Subcutaneous Vaccine Adjuvants Sales Market Share by Application (2019-2024)
Table 63. Global Subcutaneous Vaccine Adjuvants Sales Market Share by Application (2025-2030)
Table 64. Global Subcutaneous Vaccine Adjuvants Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Subcutaneous Vaccine Adjuvants Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Subcutaneous Vaccine Adjuvants Revenue Market Share by Application (2019-2024)
Table 67. Global Subcutaneous Vaccine Adjuvants Revenue Market Share by Application (2025-2030)
Table 68. Global Subcutaneous Vaccine Adjuvants Price (US$/Unit) by Application (2019-2024)
Table 69. Global Subcutaneous Vaccine Adjuvants Price (US$/Unit) by Application (2025-2030)
Table 70. Agenus Corporation Information
Table 71. Agenus Description and Business Overview
Table 72. Agenus Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Agenus Subcutaneous Vaccine Adjuvants Product
Table 74. Agenus Recent Developments/Updates
Table 75. Croda International Corporation Information
Table 76. Croda International Description and Business Overview
Table 77. Croda International Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Croda International Subcutaneous Vaccine Adjuvants Product
Table 79. Croda International Recent Developments/Updates
Table 80. Seppic Corporation Information
Table 81. Seppic Description and Business Overview
Table 82. Seppic Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Seppic Subcutaneous Vaccine Adjuvants Product
Table 84. Seppic Recent Developments/Updates
Table 85. OZ Biosciences Corporation Information
Table 86. OZ Biosciences Description and Business Overview
Table 87. OZ Biosciences Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. OZ Biosciences Subcutaneous Vaccine Adjuvants Product
Table 89. OZ Biosciences Recent Developments/Updates
Table 90. Phibro Animal Health Corporation Information
Table 91. Phibro Animal Health Description and Business Overview
Table 92. Phibro Animal Health Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Phibro Animal Health Subcutaneous Vaccine Adjuvants Product
Table 94. Phibro Animal Health Recent Developments/Updates
Table 95. Associated British Foods Corporation Information
Table 96. Associated British Foods Description and Business Overview
Table 97. Associated British Foods Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Associated British Foods Subcutaneous Vaccine Adjuvants Product
Table 99. Associated British Foods Recent Developments/Updates
Table 100. InvivoGen Corporation Information
Table 101. InvivoGen Description and Business Overview
Table 102. InvivoGen Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. InvivoGen Subcutaneous Vaccine Adjuvants Product
Table 104. InvivoGen Recent Developments/Updates
Table 105. Merck KGaA Corporation Information
Table 106. Merck KGaA Description and Business Overview
Table 107. Merck KGaA Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Merck KGaA Subcutaneous Vaccine Adjuvants Product
Table 109. Merck KGaA Recent Developments/Updates
Table 110. CSL Limited Corporation Information
Table 111. CSL Limited Description and Business Overview
Table 112. CSL Limited Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. CSL Limited Subcutaneous Vaccine Adjuvants Product
Table 114. CSL Limited Recent Developments/Updates
Table 115. GSK Corporation Information
Table 116. GSK Description and Business Overview
Table 117. GSK Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. GSK Subcutaneous Vaccine Adjuvants Product
Table 119. GSK Recent Developments/Updates
Table 120. Dynavax Technologies Corporation Information
Table 121. Dynavax Technologies Description and Business Overview
Table 122. Dynavax Technologies Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Dynavax Technologies Subcutaneous Vaccine Adjuvants Product
Table 124. Dynavax Technologies Recent Developments/Updates
Table 125. Novavax Corporation Information
Table 126. Novavax Description and Business Overview
Table 127. Novavax Subcutaneous Vaccine Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Novavax Subcutaneous Vaccine Adjuvants Product
Table 129. Novavax Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Subcutaneous Vaccine Adjuvants Distributors List
Table 133. Subcutaneous Vaccine Adjuvants Customers List
Table 134. Subcutaneous Vaccine Adjuvants Market Trends
Table 135. Subcutaneous Vaccine Adjuvants Market Drivers
Table 136. Subcutaneous Vaccine Adjuvants Market Challenges
Table 137. Subcutaneous Vaccine Adjuvants Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Subcutaneous Vaccine Adjuvants
Figure 2. Global Subcutaneous Vaccine Adjuvants Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Subcutaneous Vaccine Adjuvants Market Share by Type in 2023 & 2030
Figure 4. Infectious Diseases Product Picture
Figure 5. Cancer Product Picture
Figure 6. Others Product Picture
Figure 7. Global Subcutaneous Vaccine Adjuvants Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Subcutaneous Vaccine Adjuvants Market Share by Application in 2023 & 2030
Figure 9. Research Applications
Figure 10. Commercial Applications
Figure 11. Global Subcutaneous Vaccine Adjuvants Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Subcutaneous Vaccine Adjuvants Market Size (2019-2030) & (US$ Million)
Figure 13. Global Subcutaneous Vaccine Adjuvants Sales (2019-2030) & (K Units)
Figure 14. Global Subcutaneous Vaccine Adjuvants Average Price (US$/Unit) & (2019-2030)
Figure 15. Subcutaneous Vaccine Adjuvants Report Years Considered
Figure 16. Subcutaneous Vaccine Adjuvants Sales Share by Manufacturers in 2023
Figure 17. Global Subcutaneous Vaccine Adjuvants Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Subcutaneous Vaccine Adjuvants Players: Market Share by Revenue in 2023
Figure 19. Subcutaneous Vaccine Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Subcutaneous Vaccine Adjuvants Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Subcutaneous Vaccine Adjuvants Sales Market Share by Country (2019-2030)
Figure 22. North America Subcutaneous Vaccine Adjuvants Revenue Market Share by Country (2019-2030)
Figure 23. United States Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Subcutaneous Vaccine Adjuvants Sales Market Share by Country (2019-2030)
Figure 26. Europe Subcutaneous Vaccine Adjuvants Revenue Market Share by Country (2019-2030)
Figure 27. Germany Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Subcutaneous Vaccine Adjuvants Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Subcutaneous Vaccine Adjuvants Revenue Market Share by Region (2019-2030)
Figure 34. China Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Subcutaneous Vaccine Adjuvants Sales Market Share by Country (2019-2030)
Figure 44. Latin America Subcutaneous Vaccine Adjuvants Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Subcutaneous Vaccine Adjuvants Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Subcutaneous Vaccine Adjuvants Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Subcutaneous Vaccine Adjuvants Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Subcutaneous Vaccine Adjuvants by Type (2019-2030)
Figure 54. Global Revenue Market Share of Subcutaneous Vaccine Adjuvants by Type (2019-2030)
Figure 55. Global Subcutaneous Vaccine Adjuvants Price (US$/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Subcutaneous Vaccine Adjuvants by Application (2019-2030)
Figure 57. Global Revenue Market Share of Subcutaneous Vaccine Adjuvants by Application (2019-2030)
Figure 58. Global Subcutaneous Vaccine Adjuvants Price (US$/Unit) by Application (2019-2030)
Figure 59. Subcutaneous Vaccine Adjuvants Value Chain
Figure 60. Subcutaneous Vaccine Adjuvants Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
